Abstract: The disclosure provides a CD169 high affinity anti-tumor compound (TCC-Neu5A) and its preparation and application. The CD169 high affinity anti-tumor compound is a small molecule compound, which has specific and broad-spectrum tumor killing characteristics. TCC-Neu5Ac could targets tumor cells in vivo and metabolize onto a surface of the tumor cells to form CD169 ligands. These tumor cells are recognized and phagocytized by CD169-positive macrophages, which then release tumor-related antigens and present them to other immune cells, triggering an anti-tumor immune response. The CD169 high affinity anti-tumor compound provided by the disclosure is effective for a variety of tumors and has an inhibitory effect on tumor metastasis. In addition, the CD169 high affinity anti-tumor compound provided by the disclosure can not only be injected but also be orally administered. Cytotoxicity and animal toxicity of the CD169 high affinity anti-tumor compound are very low.

Abstract: The present invention relates to a composition for viral RNA extraction and a viral RNA extraction method using the same, wherein various contaminants (e.g., fungi, bacteria, pollens, etc.) can be effectively removed from samples and thus the diagnosis of sample-derived viruses can be attained more sensitively, and more cheap reagents compared with existing compositions for RNA extraction are used and thus the scales of diagnosis tests of disease-mediated viruses and various monitoring programs can be further enlarged, thereby contributing to public health.

Abstract: A packaging system for the storage of an ophthalmic device includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more crosslinked polymeric networks. The one or more crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a first crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan. The aqueous packaging solution has an osmolality of at least about 180 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.

Abstract: Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.

Abstract: A process includes: (a) providing an initial cellulose ether powder containing 0.5 to 10 weight-percent water based on total cellulose ether powder weight; (b) heating the initial cellulose ether powder to a temperature in a range of 30 to 130 degrees Celsius; (c) before, during and/or after heating in step (b), adding solid base to the cellulose ether powder and mixing with the initial cellulose ether powder to form a cellulose ether/base mixture; (d) adding volatile acid to the cellulose ether/base mixture and mixing; and (e) allowing the volatile acid to hydrolyze the initial cellulose ether to form a final cellulose ether having a lower viscosity than the initial cellulose ether.

Abstract: The present disclosure relates to phosphorylated hexaacyl disaccharide (PHAD) compounds, compositions, and methods for treating or preventing infections.

Abstract: The present disclosure provides for improved binder compositions comprising an amine component, as well as methods for manufacturing articles and collections of matter comprising the disclosed binder compositions.

Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and treatment with one or more proton motive force (PMF) stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known.

Abstract: The present invention concerns cobalamin derivatives of formula (I) wherein X is a ligand having a formula selected from among: —(CH2)1-5—S—(CH2)0-3—CH3, —S—(CH2)1-5—NH2 and further wherein R1 is H, methyl or ethyl, R2 is and R3 is —H or and its use in diseases caused by lack of vitamin B12 support.

Abstract: The invention discloses a myrtle polysaccharide P1, the separation method thereof and the use in preparing hypolipidemic drugs therefor, wherein the P1 contains 6.74% of ribose, 1.73% of rhamnose, 60.06% of arabinose, 3.54% of xylose, 5.64% of mannose, 13.16% of glucose, and 9.13% of galactose. The experiment result shows that the myrtle polysaccharide P1 has a certain ability to bind cholate in vitro. Taking cholestyramine as a positive control and the binding rate of cholestyramine to each cholate as 100%, the relative binding rate of the myrtle polysaccharide P1 to sodium taurocholate, sodium glycocholate and sodium cholate was 25.28%, 44.56%, and 50.10%, respectively.

Abstract: An object of the present invention is to provide an anti-tumor agent and an anti-tumor kit which have superior anti-tumor effect as compared with a therapy with gemcitabine, paclitaxel or a combination thereof; as well as an anti-tumor effect enhancer. According to the present invention, provided is an anti-tumor agent including paclitaxel or a salt thereof and 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinofuranosyl)cytosine or a salt or prodrug thereof.

Abstract: A method for producing a cellulose ether having a high viscosity while keeping the same degree of polymerization as that in the production of a shaped pulp without changing a raw material or production facility. More specifically, provided is a method for producing a cellulose ether including steps of: cutting or pulverizing pulp to obtain sheet-like, chip-like, or powdery cellulose pulp, wherein the pulp is formed in a form of roll whose surface layer on at least one of the circumferential side and the ends is removed, or in a form of bale whose surface layer on at least one side is removed; bringing the obtained cellulose pulp into contact with an alkali metal hydroxide solution to obtain alkali cellulose; reacting the alkali cellulose with an alkylating agent to obtain a reaction product mixture; and subjecting the reaction product mixture to purification to obtain the cellulose ether.

Abstract: The present disclosure discloses a processing method for intelligent hydrogel from nano-scale starch particles, and belongs to the technical field of nutritional health food. The present disclosure uses dendritic water-soluble starch particles as a skeleton and utilizes a transglycosidation and chain extension-glycan entanglement reaction of glycosyltransferase to obtain an intelligent hydrogel having a spatial reticular structure. The product provided by the present disclosure is an intelligent starch-based hydrogel which has good rehydration capability, biocompatibility, strong gel strength, enzymatic response irreversibility, pH response reversibility, can carry multiple nutritional factors. The hydrogel provided by the present disclosure can protect and control the release of food functional factors, and can be applied to food, biological drug loading, functional materials and the like.

Abstract: Problem: A malaria transmission blocker or a malaria parasite growth inhibitor is provided as a result of finding a druq which inhibits malaria parasite growth in the body of a vector mosquito. Solution: A malaria parasite growth inhibitor or transmission blocker containing a rare sugar such as D-allose or D-psicose as an active ingredient.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Provided is a process for reducing the size of ethylcellulose polymer particles comprising (a) providing a slurry comprising (i) water (ii) said ethylcellulose particles, wherein said ethylcellulose polymer particles have D50 of 100 ?m or less; (iii) surfactant comprising 1.2% or more anionic surfactants by weight based on the solid weight of said slurry, with the proviso that if the amount of anionic surfactant is 2.5% or less by weight based on the solid weight of said slurry, then said surfactant further comprises 5% or more stabilizers by weight based on the solid weight of said slurry, wherein said stabilizer is selected from the group consisting of water-soluble polymers, water-soluble fatty alcohols, and mixtures thereof. (b) grinding said slurry in an agitated media mill having a collection of media particles having a median particle size of 550 ?m or smaller. Also provided is a dispersion made by such a process.

Abstract: Provided is a method of stably producing a water-soluble nonionic cellulose ether powder having a high bulk density at low cost by adding a minimum amount of water. More specifically provided is a method for producing a water-soluble nonionic cellulose ether powder, comprising the steps of: reacting alkali cellulose with an etherifying agent to obtain a reaction product; washing and draining the reaction product to obtain a water-soluble nonionic cellulose ether; mixing the water-soluble nonionic cellulose ether with such an amount of water of 70° C. or higher as to make a water content of the water-soluble nonionic cellulose ether become 55 to 90% by weight to obtain a water-containing water-soluble nonionic cellulose ether having a water content of 55 to 90% by weight; cooling the water-containing water-soluble nonionic cellulose ether; and drying and pulverizing the cooled water-containing water-soluble nonionic cellulose ether.

Abstract: The present disclosure discloses a method for extracting a RG-I-rich pectic polysaccharide. The method comprises the following steps: mixing and stirring a citrus fruit peel powder and a dilute hydrochloric acid solution at a low temperature to destroy cell walls of citrus peels, filtering, and then mixing the retentate with a sodium hydroxide solution for low temperature extraction, adding ethanol to the solution obtained by filtering to precipitate, and washing the obtained polysaccharide with ethanol and drying to obtain the above pectic polysaccharide. Compared with the traditional extraction method, this method reduces the hydrolysis of pectin side chains by controlling the extraction temperature, and the extracted pectic polysaccharide is rich in RG-I domain and has higher biological activity such as cancer and cardiovascular disease prevention. Energy can be greatly saved because of the low extraction temperature.

Abstract: New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.